-
BioJet LLC Obtains License for Pharmaceutical Production
Read more: BioJet LLC Obtains License for Pharmaceutical ProductionIn November 2025, the production facility of BioJet LLC in Pechatniki successfully passed an inspection by the Russian Ministry of Industry and Trade. Based on the results, the company was granted a License to manufacture medicinal pharmaceutical products. License registration number: L012-00102-77/03725316, issued on November 13, 2025.
-
Alikhanov: At Least 10 Pharmaceutical Manufacturing Facilities to Be Built in Russia by 2030
Read more: Alikhanov: At Least 10 Pharmaceutical Manufacturing Facilities to Be Built in Russia by 2030By 2030, Russia plans to build at least 10 new pharmaceutical manufacturing facilities, Russian Minister of Industry and Trade Anton Alikhanov said at a meeting between President Vladimir Putin and members of the government. “The industrial base of the sector has largely been formed. By 2030, it is planned to build at least 10 additional…
-
Ministry of Industry and Trade: The Share of Domestic Medicines in Russia Has Exceeded 60%
Read more: Ministry of Industry and Trade: The Share of Domestic Medicines in Russia Has Exceeded 60%The share of domestically produced medicines in Russia stands at 63%, and exceeds 80% in government procurement, Russian Minister of Industry and Trade Anton Alikhanov reported at a meeting attended by Russian President Vladimir Putin devoted to the results of the December “Direct Line.” “The expansion of production capacity has enabled us to reach a…
-
Special Procedure for the Sale of Foreign Medicines Extended Until the End of 2027
Read more: Special Procedure for the Sale of Foreign Medicines Extended Until the End of 2027The special procedure for the sale in Russia of registered foreign medicinal products will remain in effect until December 31, 2027, according to the government’s press service. The measure concerns the possibility of selling foreign medicines in their original foreign packaging. “At the same time, the label must be in Russian,” the statement says. The…
-
A Drug for Hepatitis B Therapy Developed in Russia
Read more: A Drug for Hepatitis B Therapy Developed in RussiaRussian scientists have developed a drug for the treatment of hepatitis B based on CRISPR/Cas9 technology. A hepatitis B therapy based on gene-editing technology has been developed in Russia, Sechenov University reported. “We have developed a new non-viral delivery system based on biodegradable nanoparticles. For the first time, we have learned how to package CRISPR/Cas…
-
Methodological Guidelines Approved for Assessing Technological Processes in Pharmaceutical Manufacturing to Implement Government Resolution No. 719
Read more: Methodological Guidelines Approved for Assessing Technological Processes in Pharmaceutical Manufacturing to Implement Government Resolution No. 719Starting July 1, 2026, Government Resolution of the Russian Federation No. 1392 dated September 10, 2025, “On Amendments to Government Resolution of the Russian Federation No. 719 dated July 17, 2015,” will enter into force. The resolution introduces a points-based system for determining the country of origin of pharmaceutical products. To implement this resolution, the…
-
The average cost of bringing a medicinal product to market has tripled over 20 years
Read more: The average cost of bringing a medicinal product to market has tripled over 20 yearsOver the past 20 years, the average cost of bringing a medicinal product to market has increased approximately threefold, reaching $2.5 billion, while the probability of success for an individual molecule at the late stages of clinical trials, according to Morgan Stanley estimates, has remained at just 8–12%. Against this backdrop, the traditional R&D model…
-
More than 60% of the Russian pharmaceutical market is occupied by foreign drugmakers
Read more: More than 60% of the Russian pharmaceutical market is occupied by foreign drugmakersDespite sanctions and expectations of a complete withdrawal of foreign businesses, international pharmaceutical companies continue to hold key positions in the Russian medicines market. Based on the results of the first ten months of 2025, they account for more than 60% of sales in value terms and 36.9% in volume. International presence is especially pronounced…
-
The Ministry of Industry and Trade will align the regulatory framework with the transition to EAEU GMP
Read more: The Ministry of Industry and Trade will align the regulatory framework with the transition to EAEU GMPThe Ministry of Industry and Trade of Russia has prepared a draft government resolution proposing that, as of March 1, 2026, certain provisions of regulatory acts granting the ministry authority to confirm compliance of pharmaceutical manufacturers with Good Manufacturing Practice (GMP) requirements under national rules be declared invalid. This is another step toward formalizing the…
-
WHO Director-General: Pandemic agreement to be opened for signature after May
Read more: WHO Director-General: Pandemic agreement to be opened for signature after MayWHO member states are negotiating an important annex to the agreement — a pathogen access and genetic information-sharing system, said Tedros Adhanom Ghebreyesus. The pandemic agreement may be opened for signature after the 79th session of the World Health Assembly, which will be held in Geneva from May 18 to 23. This was announced by…